| Autor: |
Tuttle, Dylan J, Castanha, Priscila M S, Nasser, Amro, Wilkins, Maris S, Galarza, Tamara García, Alaoui-El-Azher, Mounia, Cuff, Deirdre E, Chhibbar, Prabal, Das, Jishnu, Li, Yijia, Barratt-Boyes, Simon M, Mailliard, Robbie B, Sluis-Cremer, Nicolas, Rinaldo, Charles R, Marques, Ernesto T A |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 4/15/2024, Vol. 229 Issue 4, p1147-1157, 11p |
| Abstrakt: |
Background Immune dysregulation in people with human immunodeficiency virus-1 (PWH) persists despite potent antiretroviral therapy and, consequently, PWH tend to have lower immune responses to licensed vaccines. However, limited information is available about the impact of mRNA vaccines in PWH. This study details the immunologic responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in PWH and their impact on HIV-1. Methods We quantified anti-S immunoglobulin G (IgG) binding and neutralization of 3 SARS-CoV-2 variants of concern and complement activation in blood from virally suppressed men with HIV-1 (MWH) and men without HIV-1 (MWOH), and the characteristics that may impact the vaccine immune responses. We also studied antibody levels against HIV-1 proteins and HIV-1 plasma RNA. Results MWH had lower anti-S IgG binding and neutralizing antibodies against the 3 variants compared to MWOH. MWH also produced anti-S1 antibodies with a 10-fold greater ability to activate complement and exhibited higher C3a blood levels than MWOH. MWH had decreased residual HIV-1 plasma viremia and anti-Nef IgG approximately 100 days after immunization. Conclusions MWH respond to SARS-CoV-2 mRNA vaccines with lower antibody titers and with greater activation of complement, while exhibiting a decrease in HIV-1 viremia and anti-Nef antibodies. These results suggest an important role of complement activation mediating protection in MWH. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
